Halozyme Therapeutics (HALO) Debt to Equity (2013 - 2026)
Halozyme Therapeutics (HALO) reported Debt to Equity of $9.76 for Q1 2026, up 212.39% year-over-year from $3.13 in Q1 2025, and down 77.75% quarter-over-quarter from $43.89 in Q4 2025.
Halozyme Therapeutics (HALO) Debt to Equity (2013 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 14 years of Debt to Equity data on file, last reported at $9.76 in Q1 2026.
- Debt to Equity for Q1 2026 came in at $9.76, up 212.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.76 (up 212.39% YoY), and the FY2025 annual result was $43.89, up 960.53% from the prior year.
- Debt to Equity declined to $9.76 in Q1 2026 per HALO's latest filing, from $43.89 in the prior quarter.
- Over five years, Debt to Equity peaked at $43.89 in Q4 2025 and troughed at $0.34 in Q2 2022.
- A 5-year average of $9.82 and a median of $6.01 in 2023 frame the typical range for Debt to Equity.
- The sharpest annual moves came in 2023 and 2024: Debt to Equity soared 6495.68% in 2023, then tumbled 76.86% in 2024.
- A 5-year view of Debt to Equity shows it stood at $8.87 in 2022, then soared by 101.68% to $17.89 in 2023, then plunged by 76.86% to $4.14 in 2024, then soared by 960.53% to $43.89 in 2025, then plunged by 77.75% to $9.76 in 2026.
- Business Quant data shows HALO's Debt to Equity at $9.76 in Q1 2026, $43.89 in Q4 2025, and $3.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 9.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.76 |
| Dec 31, 2025 | 43.89 |
| Sep 30, 2025 | 3.00 |
| Jun 30, 2025 | 4.54 |
| Mar 31, 2025 | 3.13 |
| Dec 31, 2024 | 4.14 |
| Sep 30, 2024 | 3.32 |
| Jun 30, 2024 | 5.19 |
| Mar 31, 2024 | 8.44 |
| Dec 31, 2023 | 17.89 |
| Sep 30, 2023 | 6.01 |
| Jun 30, 2023 | 9.91 |
| Mar 31, 2023 | 22.69 |
| Dec 31, 2022 | 8.87 |
| Sep 30, 2022 | 15.51 |
| Jun 30, 2022 | 0.34 |
| Mar 31, 2022 | 0.34 |
| Dec 31, 2021 | 4.45 |
| Sep 30, 2021 | 0.32 |
| Jun 30, 2021 | 0.74 |